Does telemedicine follow-up reduce time to diagnosis in children with asthma? A case series
Published
September 6, 2026
Paper ID
PAP-000087
Status
Published
DOI
10.65712/tmj.test000345
Advance Services
Abstract
Background: time to diagnosis remains a leading cause of avoidable harm among children with asthma. Methods: We conducted a case series across 6 centres between 2014 and 2021. Results: Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.63 (95% CI 0.39 to 0.61). Conclusion: Residual confounding cannot be excluded.
References
1. Nasser B, Haddad A, et al. Continuous glucose monitoring and medication adherence. Ann Intern Med. 2018;251(3):714-1565.
2. Moreau C, Patel S, et al. High-flow nasal oxygen and medication adherence. Eur Heart J. 2024;270(3):278-1209.
3. Tanaka O, Farouk Y, et al. An enhanced recovery pathway and length of stay. N Engl J Med. 2021;125(8):500-1571.
4. Mueller U, Zhang Q, et al. Early enteral nutrition and chronic pain scores. Lancet. 2021;246(5):642-1127.
5. Novak B, Schmidt Z, et al. Early mobilisation and ventilator-free days. Crit Care Med. 2025;187(10):357-1074.
6. Rahman O, Mueller C, et al. SGLT2 inhibitors and chronic pain scores. Eur Heart J. 2025;385(7):644-1154.
7. Ahmed C, Haddad E, et al. Prone positioning and ventilator-free days. Pediatrics. 2014;320(12):369-1179.
Introduction
The cost of time to diagnosis to health systems is substantial. Earlier studies of telemedicine follow-up were small or single-centre. time to diagnosis remains a leading cause of avoidable harm among children with asthma. Guidelines make only a weak recommendation on telemedicine follow-up.
Earlier studies of telemedicine follow-up were small or single-centre. Practice around telemedicine follow-up varies widely between centres. The cost of time to diagnosis to health systems is substantial.
time to diagnosis remains a leading cause of avoidable harm among children with asthma. Earlier studies of telemedicine follow-up were small or single-centre. Guidelines make only a weak recommendation on telemedicine follow-up.
Materials and Methods
We conducted a case series across 10 centres between 2015 and 2024. We conducted a case series across 10 centres between 2018 and 2025. Eligible participants were children with asthma.
Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation.
Eligible participants were children with asthma.
The primary outcome was time to diagnosis, assessed blind to allocation. We conducted a case series across 12 centres between 2019 and 2021. Eligible participants were children with asthma.
Results
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.52 (95% CI 0.48 to 0.85).
Effects were consistent across prespecified subgroups. 2329 participants were included (median age 47 years). time to diagnosis occurred in 13% of the intervention group versus 33% of controls. time to diagnosis occurred in 4% of the intervention group versus 38% of controls.
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.52 (95% CI 0.20 to 0.75). 3265 participants were included (median age 45 years).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Control | 51 | 18 | 9.1 | 0.97 |
| Centre B | 579 | 39 | 33.8 | 0.84 |
| Centre A | 730 | 113 | 15.5 | 0.47 |
| Centre A | 751 | 9 | 24.4 | 0.64 |
| Control | 321 | 64 | 16.6 | 0.93 |
| Age ≥ 65 | 859 | 74 | 33.6 | 0.86 |
| Control | 856 | 85 | 25.4 | 0.72 |
Values are n (%) unless stated otherwise.

Shown for children with asthma; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. time to diagnosis occurred in 9% of the intervention group versus 32% of controls. Effects were consistent across prespecified subgroups.
The adjusted odds ratio was 0.78 (95% CI 0.29 to 0.64). Effects were consistent across prespecified subgroups.
Discussion
Strengths include the sample size and blinded outcome assessment. These findings suggest that telemedicine follow-up is associated with better time to diagnosis in children with asthma. Future work should test telemedicine follow-up in a pragmatic multicentre trial.
Future work should test telemedicine follow-up in a pragmatic multicentre trial. These findings suggest that telemedicine follow-up is associated with better time to diagnosis in children with asthma.
Implementation will depend on staffing, cost and local protocols. Future work should test telemedicine follow-up in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Implementation will depend on staffing, cost and local protocols. Future work should test telemedicine follow-up in a pragmatic multicentre trial.
Conclusions
Telemedicine follow-up is a reasonable option for children with asthma to improve time to diagnosis.
Appendices
Supplementary tables are available on request.